Bleomycin

All ESMO 2014 abstracts with reference to bleomycin are listed below

• 1462TiP - Phase I/II study of electrochemotherapy with intravenous bleomycin and variable geometry electric fields for the treatment of deep and large soft tissue tumors
• 855P - Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: A systematic review and meta-analysis of patient outcomes
• 856P - Chemotherapy (CT) intensification in patients (pts) with metastatic seminoma who have negative prognostic factors
• 857P - Interim [18F] fluorodeoxyglucose positron emission tomography (PET) for early metabolic assessment of response to PEB chemotherapy for metastatic seminoma: Preliminary findings
• 858P - Complications during cisplatin based primary chemotherapy in patients with testicular cancer: Is there a need for thromboembolic prophylaxis
• 859P - Clinical outcomes of poor prognosis germ cell tumors (GCT): An analysis of a series from a single referral center
• 872TiP - ANZUP 1302: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours (P3BEP)
• 874TiP - ANZUP 1302 P3BEP companion translational study: Prospective collection of whole blood, serum, plasma and tumour tissue in a randomized trial of chemotherapy for metastatic germ cell tumours (GCT)
• 900P - Prognostic significance of serum alphafoetoprotein early decline in ovarian yolk sac tumor
• 903P - Effectiveness and toxicity of vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin and etoposide (VPCBAE) in the management of patients with small cell carcinoma of the ovary-hypercalcemic type (SCCOHT)
• 946O - Results of interim analysis of prospective randomized multicenter open-label study in comparison of efficacy and toxicity of BEACOPP-14 and BEACOPP-esc regimens in patients with Hodgkin's lymphoma from poor-prognosis group
• 951P - The role of microenvironment expression of PD-1 ligands and chemokines in clinical outcome of Hodgkin's lymphoma